Latin America's MedTech market access landscape shifted on three fronts this week: Ecuador published a decade-overdue device registration overhaul, Argentina restructured its ANMAT import fee schedule, and Colombia's INVIMA executed two bilateral cooperation agreements that point toward gradual regulatory convergence across the Andean and Central American corridors.
Argentina · Colombia · Ecuador · El Salvador · Latin America · LATAM · Mercosur
ARCSA's Resolution ARCSA-DE-2026-003-DASP, signed April 28 and published in the Registro Oficial on May 18, replaces Ecuador's decade-old device framework with a four-tier risk classification system aligned to IMDRF principles, a simplified registration pathway for devices already approved by high-vigilance jurisdictions, and tighter post-market vigilance requirements (Lexis Ecuador). Establishments handling storage, distribution and transport of devices must now hold the corresponding good-practices certification, and low-risk devices and condoms remain freely commercializable provided baseline sanitary requirements are met.
For MedTech companies, the simplified pathway is the most consequential change. Devices previously cleared by IMDRF-aligned agencies — FDA, EMA, Health Canada, TGA, ANVISA among others — can now use that prior clearance as the foundation of an ARCSA submission, materially compressing time-to-market in Ecuador and converting it into a viable second- or third-wave LATAM filing rather than a standalone effort.
Why It Matters: Ecuador has effectively re-entered the LATAM device map. Sponsors building 2026-2027 regional registration roadmaps should re-evaluate ARCSA's placement in their filing sequence, particularly for Class I and II devices where the simplified pathway will deliver the steepest reductions in review time.
ANMAT published Disposición 2978/2026 on May 19, replacing its fixed-range import tariff scales with a FOB-based percentage schedule that takes effect June 1, 2026 (Infobae, La Nación). For medical products specifically, the cutoff is set at ARS $55 million FOB value: imports below that threshold pay 1.5%, above it 1.25% — replacing the previous 3% to 5% fixed-range structure. ANMAT estimates roughly 75% of importers across all categories will pay less under the new scheme.
The same disposition also updated fees for product registrations, manufacturing-site enablements, exporter certifications and INPM (Instituto Nacional de Productos Médicos) practices, signaling a broader reorganization of ANMAT's fee architecture beyond import operations alone.
Bottom Line: For MedTech distributors holding Argentine portfolios, the cost reduction is material — but the June 1 effective date is the operationally relevant deadline. Importers should reconcile pending shipments and Q2 cost models against the new FOB-percentage methodology immediately rather than after publication settles.
INVIMA executed two bilateral memoranda of understanding in mid-May, both covering medical devices among other sanitary products. The ARCSA-INVIMA agreement establishes cooperation in regulation, quality control and certification across medicines, food, medical devices and cosmetics, with provisions for exchange of technical capacity (INVIMA). Days later, INVIMA announced a parallel MoU with El Salvador's Dirección Nacional de Medicamentos focused on joint sanitary activities, information exchange and gradual regulatory convergence (INVIMA Sala de Prensa).
Neither agreement constitutes mutual recognition, but both extend INVIMA's bilateral footprint at a moment when the agency is positioning itself — visibly — as a regional regulatory hub. The ARCSA pact in particular complements Ecuador's new IMDRF-aligned framework, opening the door to future reliance-based pathways between two of the Andean Community's most active device markets.
What to Focus On: These MoUs are precursors, not endpoints. The actionable signal for MedTech companies is that Ecuador and Colombia are now formally aligned on regulatory convergence — making dual-country dossier strategies more defensible than at any point in the past decade.
Need help navigating LATAM regulatory pathways? bioaccess® provides market access services with U.S. regulatory anchoring and Latin American execution — from device registration to commercial launch. Visit bioaccessla.com/market-access.
← All LATAM Regulatory Dispatch editions · Contact bioaccess®